Valentine M. Macaulay

6.0k citations

73 papers · 4.5k indexed · 1 hit paper · h-index 35

Molecular Biology top 2%
Endocrinology, Diabetes and Metabolism top 0.5%
Cancer Research top 1%
Oncology top 2%
Pulmonary and Respiratory Medicine top 5%

Co-authors: Johann Riedemann Andrew Protheroe J.S.P. Yuen Martin P. Playford Meenali Chitnis Simon Brewster Erin A. Bohula Giles Hellawell
Topics: Growth Hormone and Insulin-like Growth Factors (30 papers)Cancer, Hypoxia, and Metabolism (14 papers)Metabolism, Diabetes, and Cancer (13 papers)
Cited by: Endocrinology, Diabetes and Metabolism Cancer Research Oncology
Journals: Proceedings of the National Academy of Sciences Nucleic Acids Research Journal of Biological Chemistry
Partner nations: United Kingdom United States Austria

In The Last Decade

Valentine M. Macaulay

72 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Insulin-like growth factors and cancer

1992 513 citations Valentine M. Macaulay British Journal of Cancer profile →

Peers

Countries citing papers authored by Valentine M. Macaulay

Since Specialization

Citations

This map shows the geographic impact of Valentine M. Macaulay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valentine M. Macaulay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valentine M. Macaulay more than expected).

Fields of papers citing papers by Valentine M. Macaulay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Valentine M. Macaulay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valentine M. Macaulay. The network helps show where Valentine M. Macaulay may publish in the future.

Co-authorship network of co-authors of Valentine M. Macaulay

This figure shows the co-authorship network connecting the top 25 collaborators of Valentine M. Macaulay. A scholar is included among the top collaborators of Valentine M. Macaulay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Valentine M. Macaulay. Valentine M. Macaulay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer 2023 ·British Journal of Cancer ·Valentine M. Macaulay,Simon Lord,Syed A. Hussain,Pablo Maroto,Robert H. Jones,Miguel Ángel Climent,Natalie Cook,Chia‐Chi Lin,Shian‐Shiang Wang,Diletta Bianchini,Mark Bailey,(unknown),Thomas Bogenrieder,Johann S. de Bono	3
2	Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction 2021 ·Cancer Research ·Guillaume Rieunier,Xiaoning Wu,(unknown),(unknown),(unknown),(unknown),(unknown),Stephanie B. Hatch,Daniel Ebner,Lisa K. Folkes,Ulrike Weyer-Czernilofsky,Thomas Bogenrieder,Anderson J. Ryan,Valentine M. Macaulay	9
3	Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis 2019 ·Clinical Cancer Research ·Guillaume Rieunier,Xiaoning Wu,Valentine M. Macaulay,Adrian V. Lee,Ulrike Weyer-Czernilofsky,Thomas Bogenrieder	38
4	Radioresistant laryngeal cancers upregulate type 1 IGF receptor and exhibit increased cellular dependence on IGF and EGF signalling 2019 ·Clinical Otolaryngology ·Ali Qureishi,Guillaume Rieunier,Ketan Shah,Tamara Aleksic,Stuart C. Winter,Henrik Møller,Valentine M. Macaulay	5
5	Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage 2018 ·Cancer Research ·Tamara Aleksic,Nicki Gray,Xiaoning Wu,Guillaume Rieunier,(unknown),(unknown),Clare Verrill,Richard J. Bryant,Cheng Han,(unknown),Adam Lambert,Rajeev Kumar,Freddie C. Hamdy,Ulrike Weyer-Czernilofsky,Michael P. Sanderson,Thomas Bogenrieder,Stephen Taylor,Valentine M. Macaulay	50
6	TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy 2017 ·British Journal of Cancer ·Giacomo Pirovano,Thomas M. Ashton,Katharine Herbert,Richard J. Bryant,Clare Verrill,Lucia Cerundolo,Francesca M. Buffa,Remko Prevo,(unknown),Anderson J. Ryan,Valentine M. Macaulay,W. Gillies McKenna,Geoff S. Higgins	22
7	Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies 2017 ·Targeted Oncology ·(unknown),(unknown),Valentine M. Macaulay,Ulrike Weyer-Czernilofsky,Thomas Bogenrieder	125
8	Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR 2016 ·Frontiers in Oncology ·Tamara Aleksic,Lisa Browning,(unknown),Rachel R. Phillips,Suzanne Page,Shirley Henderson,Nicholas A. Athanasou,Olaf Ansorge,Duncan Whitwell,Sarah Pratap,A. Bassim Hassan,Mark R. Middleton,Valentine M. Macaulay	31
9	Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation 2015 ·Cancer Cell ·Sophia X. Pfister,Enni Markkanen,Yanyan Jiang,Sovan Sarkar,Mick Woodcock,Giulia Orlando,Ioanna Mavrommati,Chen‐Chun Pai,Lykourgos‐Panagiotis Zalmas,Neele Drobnitzky,Grigory L. Dianov,Clare Verrill,Valentine M. Macaulay,Songmin Ying,Nicholas B. La Thangue,Vincenzo D’Angiolella,Anderson J. Ryan,Timothy C. Humphrey	224
10	Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle‐invasive transitional cell carcinoma of the bladder 2012 ·Cancer ·Christopher Blick,Peter Hall,(unknown),(unknown),Jeremy Crew,Thomas Powles,Valentine M. Macaulay,Nicholas P. Munro,David Douglas,(unknown),Andrew Protheroe,John Chester	35
11	Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks 2012 ·Radiotherapy and Oncology ·Benjamin W. Turney,Martin Kerr,Meenali Chitnis,(unknown),Yong Wang,Johann Riedemann,Mark Rochester,Andrew Protheroe,Simon Brewster,Valentine M. Macaulay	37
12	Type 1 Insulin-like Growth Factor Receptor Translocates to the Nucleus of Human Tumor Cells 2010 ·Cancer Research ·Tamara Aleksic,Meenali Chitnis,Olga V. Perestenko,Shan Gao,Peter H. Thomas,Gareth D. H. Turner,Andrew Protheroe,Mark Howarth,Valentine M. Macaulay	169
13	An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib 2009 ·Urologic Oncology Seminars and Original Investigations ·(unknown),Valentine M. Macaulay,S. A. Roberts,Mark Sullivan,Andrew Protheroe	13
14	Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer 2008 ·Expert Opinion on Therapeutic Targets ·J.S.P. Yuen,Valentine M. Macaulay	94
15	The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma 2007 ·Oncogene ·J.S.P. Yuen,Matthew E. Cockman,Mark Sullivan,Andrew Protheroe,Gareth D. H. Turner,Ian S. Roberts,Christopher W. Pugh,Haim Werner,Valentine M. Macaulay	75
16	Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer 2004 ·Cancer Gene Therapy ·Mark Rochester,Johann Riedemann,Giles Hellawell,Simon Brewster,Valentine M. Macaulay	93
17	An in vivo model of intratumoural aromatase using aromatase‐transfected MCF7 human breast cancer cells 1995 ·International Journal of Cancer ·(unknown),Valentine M. Macaulay,(unknown),Simone Detre,Alan Ashworth,M Dowsett	21
18	Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells 1994 ·British Journal of Cancer ·Valentine M. Macaulay,(unknown),(unknown),M.G. Rowlands,Mitch Dowsett,Alan Ashworth	29
19	Insulin-like growth factors and cancerbreakdown → 1992 ·British Journal of Cancer ·Valentine M. Macaulay	513
20	Somatostatin receptors are present in small‐cell but not in non‐small‐cell primary lung carcinomas: Relationship to EGF‐receptors 1990 ·International Journal of Cancer ·J.C. Reubi,Beatrice Waser,Mary N. Sheppard,Valentine M. Macaulay	86

About Valentine M. Macaulay

Valentine M. Macaulay is a scholar working on Endocrinology, Diabetes and Metabolism, Cancer Research and Oncology, having authored 73 papers that have together received 4.5k indexed citations. Recurring topics across this work include Growth Hormone and Insulin-like Growth Factors (30 papers), Cancer, Hypoxia, and Metabolism (14 papers) and Metabolism, Diabetes, and Cancer (13 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.7k citations), Cancer Research (1.3k citations) and Oncology (1.3k citations). Valentine M. Macaulay has collaborated with scholars based in United Kingdom, United States and Austria. Frequent co-authors include Johann Riedemann, Andrew Protheroe, J.S.P. Yuen, Martin P. Playford, Meenali Chitnis, Simon Brewster, Erin A. Bohula, Giles Hellawell, Gareth D. H. Turner and Tamara Aleksic. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact